Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05871021 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

Study acronym: PRIDE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Apr 10, 2028 → Dec 31, 2028
See other at-risk trials from University Hospital Tuebingen

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Apr 10, 2028 to Dec 31, 2028 Show 7 more changesShow less
    • Enrollment closed, study ongoing
    • Final enrollment: 107 participants (planned 146)
    • Study completion pushed from Jul 10, 2028 to Apr 15, 2029
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 4 of 6 entries
    • Site details revised at 9 of 9 sites
    • Publications: details revised at 1 of 1 entry
  2. Trial sites expanded: 1 → 9 locationsv4
  3. Lead sponsor: Ludwig-Maximilians - University of Munich to University Hospital Tuebingenv3 Show 4 more changesShow less
    • Primary completion date: Apr 10, 2027 to Apr 10, 2028
    • Study completion date: Jul 10, 2027 to Jul 10, 2028
    • Eligibility criteria expanded, about 50 words
    • Site details revised
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Oct 1, 2026 to Apr 10, 2027
    • Start date changed from estimate of Oct 1, 2023 to Apr 10, 2024
    • Study sites: 0 to 1
    • Study completion date: Jan 1, 2027 to Jul 10, 2027
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation isotoxically. The goal is improved survival without significantly increasing side effects. The study uses a simultaneous integrated boost with a total dose of 75 Gy in 2.5 Gy per fraction.
Trial Details
NCT Number NCT05871021
Lead Sponsor University Hospital Tuebingen
Conditions
(from sponsor)		 Glioblastoma
Related terms Glioblastoma
Enrollment 107 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov